Search Results

Sofinnova Partners announced that Dr. Joshua Makower, co-founder and director of the Stanford Byers Center for Biodesign, has joined Sofinnova as an advisory Venture Partner.

Sofinnova Partners announced that its portfolio company, Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in the development of therapeutic peptides for rare endocrine and related diseases has entered into a definitive agreement with AstraZeneca for its acquisition, with an upfront purchase price of $800 million and a potential milestone payment of $250 million.

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the strategic strengthening of its medtech acceleration team with the appointment of Mano Iyer as Partner and the promotion of Cécile Dupont to Partner.

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the launch of Biovelocita, an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.

Sofinnova Partners and Gustave Roussy announced the launch of a strategic collaboration as part of Sofinnova Biovelocita, the first pan-European investment strategy dedicated to the creation and acceleration of biotech startups.

Sofinnova Partners announced the appointment of Mary McCarthy as Partner at Sofinnova Partners, joining the growing Sofinnova Industrial Biotech Strategy team.

May Health announced it has closed a $25 million Series B financing round, co-led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets LP.

With the help of third-party investors, the new venture will focus on three genetic and rare diseases: tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced that Noema Pharma, has raised an oversubscribed CHF 103 million Series B financing round.

Pixium Vision SA announces that it successfully negotiated a 3 million Euro convertible shareholders’ loan with Bpifrance and Sofinnova.